Adamis Pharmaceuticals is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including respiratory disease, allergy and opioid overdose. Co.'s products and product candidates include: Symjepi™ (epinephrine) Injection 0.3mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; Symjepi™ (epinephrine) Injection 0.15mg for use in the treatment of anaphylaxis for patients weighing 33 to 66 pounds; a naloxone injection product candidate ZIMHI™ for the treatment of opioid overdose; a Beclomethasone metered dose inhaler product candidate (APC-1000) for the treatment of asthma; and among others. We show 31 historical shares outstanding datapoints in our coverage of ADMP's shares outstanding history.
Understanding the changing numbers of ADMP shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ADMP versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ADMP by allowing them to research ADMP shares outstanding history
as well as any other stock in our coverage universe. |
Video: Shares Outstanding Importance
